1. ANAPLASTIC LARGE CELL LYMPHOMA, ALK‐NEGATIVE: ANALYSIS OF 235 CASES COLLECTED BY THE T‐CELL PROJECT. (12th June 2019) Authors: Shustov, A.; Cabrera, M.; Bellei, M.; Civallero, M.; Ko, Y.H.; Manni, M.; Horwitz, S.M.; Antonio De Souza, C.; Radford, J.; Varela, S.B.; Prates, M.V.; Ferreri, A.; Chiattone, C.; Spina, M.; Vose, J.M.; Chiappella, A.; Laszlo, D.; Marino, D.; Stelitano, C.; Skrypets, T. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 283 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CHEMO‐FREE TRIPLET COMBINATION OF TGR‐1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL. (June 2017) Authors: Nastoupil, L.; Lunning, M.A.; Vose, J.M.; Schreeder, M.T.; Siddiqi, T.; Flowers, C.R.; Cohen, J.B.; Burger, J.A.; Wierda, W.G.; O'Brien, S.; Sportelli, P.; Miskin, H.P.; Purdom, M.A.; Weiss, M.S.; Fowler, N.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 112 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. COMBINATION OF TGR‐1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA. (June 2017) Authors: Lunning, M.A.; Vose, J.M.; Bierman, P.J.; Bociek, G.; Schreeder, M.T.; Siddiqi, T.; Blumel, S.M.; Cutter, K.; Pauli, E.K.; Bui, D.; Sportelli, P.; Miskin, H.P.; Purdom, M.; Weiss, M.S.; Fowler, N.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Follicular large cleaved cell (centrocytic) lymphoma: A distinctive but unrecognized variant of follicular lymphoma. (June 2017) Authors: Weisenburger, D.D.; El Behery, R.; Laurini, J.A.; Smith, L.M.; Dave, B.J.; Yuan, J.; Fu, K.; Chan, W.C.; Nathwani, B.N.; Bierman, P.J.; Bociek, R.G.; Vose, J.M.; Armitage, J.O.; Greiner, T.C.; Aoun, P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 285 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA. (June 2017) Authors: Herrera, A.F.; Moskowitz, A.J.; Bartlett, N.L.; Vose, J.M.; Ramchandren, R.; Feldman, T.A.; Lacasce, A.S.; Ansell, S.M.; Moskowitz, C.H.; Fenton, K.; Ogden, C.; Taft, D.; Zhang, Q.; Kato, K.; Campbell, M.; Advani, R.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PROGNOSTIC FACTORS AND IMPACT OF ETOPOSIDE IN ADULTS WITH SYSTEMIC ALK‐POSITIVE ANAPLASTIC LARGE‐CELL LYMPHOMA: A POOLED ANALYSIS OF SIX STUDIES. (June 2017) Authors: Sibon, D.; Nguyen, D.; Schmitz, N.; Suzuki, R.; Feldman, A.L.; Gressin, R.; Lamant, L.; Weisenburger, D.; Nakamura, S.; Ziepert, M.; Maurer, M.J.; Bast, M.; Armitage, J.O.; Vose, J.M.; Tilly, H.; Jais, J.P.; Savage, K.J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 240 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. SAFETY AND EFFICACY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) IN OLDER PATIENTS: RESULTS FROM THE US LYMPHOMA CAR‐T CONSORTIUM. (12th June 2019) Authors: Sano, D.; Lekakis, L.; Feng, L.; Nastoupil, L.J.; Jain, M.D.; Spiegel, J.Y.; Dahiya, S.; Lin, Y.; Ghobadi, A.; Lunning, M.; Hill, B.T.; Reagan, P.; Oluwole, O.; McGuirk, J.; Sehgal, A.; Deol, A.; Charalambos, A.; Goy, A.H.; Munoz, J.; Cashen, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 304 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗